SIC 2834 – Pharmaceutical Preparations
Valuation | |
---|---|
Market Cap ($M) | 832.52 |
Enterprise Value ($M) | 1,004.46 |
Book Value ($M) | 69.30 |
Book Value / Share | 1.94 |
Price / Book | 12.01 |
NCAV ($M) | -130.02 |
NCAV / Share | -3.65 |
Price / NCAV | -6.40 |
Profitability (mra) | |
---|---|
Return on Invested Capital (ROIC) | -0.06 |
Return on Assets (ROA) | -0.06 |
Return on Equity (ROE) | -0.29 |
Liquidity (mrq) | |
---|---|
Quick Ratio | 1.96 |
Current Ratio | 2.08 |
Balance Sheet (mrq) ($M) | |
---|---|
Current Assets | 189.65 |
Assets | 388.97 |
Liabilities | 319.67 |
Debt | n/a |
Equity | n/a |
Income Statement (mra) ($M) | |
---|---|
Revenue | 199.61 |
Operating Income | 9.07 |
Net Income | -17.48 |
Earnings Per Share Basic And Diluted | n/a |
Earnings Per Share Diluted | n/a |
Earnings Per Share Basic | n/a |
Cash Flow Statement (mra) ($M) | |
---|---|
Cash From Operations | -22.20 |
Cash from Investing | -33.16 |
Cash from Financing | 28.53 |
(click for more detail) |
File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
---|---|---|---|---|
13D/A | Baum Mark L | 10.69 | 16.30 | |
13G/A | Kaufman Daniel Louis | 4.75 | -11.69 | |
13G/A | Ophir Asset Management Pty Ltd | 2.80 | -59.64 |
Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
---|---|---|---|---|
(click for more detail) |
Date | Insider Trades | Code | Shares | Value |
---|---|---|---|---|
(click for more detail) |
File Date | Form | SEC Filings |
---|---|---|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
(click for more detail) |
Short Volume | |||
---|---|---|---|
Market Date | Short Volume | Total Volume | Short Volume Ratio |
49,326 | 166,810 | 29.57 | |
60,115 | 204,831 | 29.35 | |
104,564 | 279,323 | 37.43 | |
71,296 | 315,604 | 22.59 | |
(click for more detail) |
Similar Companies | |
---|---|
GANX – Gain Therapeutics, Inc. | GHRS – GH Research PLC |
HRMY – Harmony Biosciences Holdings, Inc. | IKNA – Ikena Oncology, Inc. |
IMRX – Immuneering Corporation |
Financial data and stock pages provided by
Fintel.io